Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
12 Months Ended
Jul. 31, 2013
Jul. 31, 2012
Jul. 31, 2011
Revenues:      
Clinical laboratory services $ 55,889 $ 59,403 $ 52,762
Product revenues 32,526 37,722 41,830
Royalty and license fee income 5,292 5,958 7,437
Total revenues 93,707 103,083 102,029
Operating expenses:      
Cost of clinical laboratory services 38,251 36,305 31,682
Cost of product revenues 16,584 19,668 22,137
Research and development 3,889 6,293 7,806
Selling, general, and administrative 43,654 47,928 45,191
Provision for uncollectible accounts receivable 4,496 5,104 4,431
Legal 5,813 3,724 3,710
Impairment charges   24,540  
Total operating expenses 112,687 143,562 114,957
Operating loss (18,980) (40,479) (12,928)
Other income (expense):      
Interest (54) 21 11
Other 5 77 45
Foreign exchange gain (loss) 80 (540) 49
Loss before income taxes (18,949) (40,921) (12,823)
Benefit (provision) for income taxes 712 1,652 (137)
Net loss $ (18,237) $ (39,269) $ (12,960)
Net loss per common share:      
Basic and diluted (in Dollars per share) $ (0.46) $ (1.01) $ (0.34)
Weighted average common shares outstanding:      
Basic and diluted (in Shares) 39,607 38,798 38,357